Trial Outcomes & Findings for High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System (NCT NCT02265848)

NCT ID: NCT02265848

Last Updated: 2016-10-25

Results Overview

Digital pain rating system that scores patient's subjective pain rating from 0 to 10; with greater number indicating progressively worsening pain. NPRS were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

22 participants

Primary outcome timeframe

Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)

Results posted on

2016-10-25

Participant Flow

All study subjects were recruited from the Carolinas Pain Institute who were implanted with Boston Scientific's Precision Plus spinal cord stimulation (SCS) system for chronic axial pain, and at the time of recruitment, was not receiving adequate pain relief from SCS system with baseline numeric pain rating scale of 5 or greater.

Randomization scheme was 1 to 1 ratio. Randomization assignment was generated using random number generator, and individual results were sealed in an envelope. If subject needed to be replaced, the replacement subject will receive the same randomization assignment.

Participant milestones

Participant milestones
Measure
Treatment Group A
Subjects randomized to the treatment group A will begin the 7 week study "per sequence" (e.g., "High frequency first, then Low frequency" and "Low frequency first, then High frequency"), with each stimulation modes lasting approximately 3 weeks with 7 to 10 days of "wash off" periods in between. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Treatment Group B
Subjects randomized to the treatment group B will begin the 7 week study "per sequence" (e.g., "Low frequency first, then High frequency" and "High frequency first, then Low frequency"), with each stimulation modes lasting approximately 3 weeks with 7 to 10 days of "wash off" periods in between. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Overall Study
STARTED
11
11
Overall Study
COMPLETED
11
11
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Treatment Group A
n=11 Participants
Subjects randomized to the treatment group A will begin the 7 week study with high frequency (1000Hz) sub-perception stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Treatment Group B
n=11 Participants
Subjects randomized to the treatment group B will begin the 7 week study with low frequency (40 to 50Hz) paresthesia capture stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency (1000Hz) sub-perception stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Total
n=22 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Age, Categorical
Between 18 and 65 years
8 Participants
n=39 Participants
9 Participants
n=41 Participants
17 Participants
n=35 Participants
Age, Categorical
>=65 years
3 Participants
n=39 Participants
2 Participants
n=41 Participants
5 Participants
n=35 Participants
Age, Continuous
59 years
n=39 Participants
56 years
n=41 Participants
57 years
n=35 Participants
Sex: Female, Male
Female
5 Participants
n=39 Participants
3 Participants
n=41 Participants
8 Participants
n=35 Participants
Sex: Female, Male
Male
6 Participants
n=39 Participants
8 Participants
n=41 Participants
14 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
11 Participants
n=39 Participants
11 Participants
n=41 Participants
22 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Asian
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=39 Participants
1 Participants
n=41 Participants
2 Participants
n=35 Participants
Race (NIH/OMB)
White
10 Participants
n=39 Participants
10 Participants
n=41 Participants
20 Participants
n=35 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Region of Enrollment
United States
11 participants
n=39 Participants
11 participants
n=41 Participants
22 participants
n=35 Participants

PRIMARY outcome

Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)

Population: All study subjects were implanted with Boston Scientific's Precision Plus spinal cord stimulation system for treatment of chronic axial pain.

Digital pain rating system that scores patient's subjective pain rating from 0 to 10; with greater number indicating progressively worsening pain. NPRS were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation.

Outcome measures

Outcome measures
Measure
Treatment Group A
n=11 Participants
Subjects randomized to the treatment group A will begin the 7 week study with high frequency (1000Hz) sub-perception stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Treatment Group B
n=11 Participants
Subjects randomized to the treatment group B will begin the 7 week study with low frequency (40 to 50Hz) paresthesia capture stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency (1000Hz) sub-perception stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Numeric Pain Rating Scale (NPRS)
Average Baseline NPRS Score
6.09 units on a scale
Interval 3.0 to 10.0
6.27 units on a scale
Interval 4.0 to 8.0
Numeric Pain Rating Scale (NPRS)
Average NPRS after Wash off
6.45 units on a scale
Interval 4.0 to 10.0
7.18 units on a scale
Interval 4.0 to 9.0
Numeric Pain Rating Scale (NPRS)
Best Baseline NPRS score
3.72 units on a scale
Interval 1.0 to 7.0
4.45 units on a scale
Interval 2.0 to 7.0
Numeric Pain Rating Scale (NPRS)
Best NPRS score after 1000 Hz. stimulation
2.64 units on a scale
Interval 1.0 to 8.0
2.18 units on a scale
Interval 1.0 to 6.0
Numeric Pain Rating Scale (NPRS)
Best NPRS score after standard stimulation
3.46 units on a scale
Interval 1.0 to 6.0
4.45 units on a scale
Interval 2.0 to 7.0
Numeric Pain Rating Scale (NPRS)
Best NPRS after Wash off
4.54 units on a scale
Interval 2.0 to 9.0
5.36 units on a scale
Interval 1.0 to 8.0
Numeric Pain Rating Scale (NPRS)
Worst Baseline NPRS score
7.90 units on a scale
Interval 6.0 to 10.0
8.09 units on a scale
Interval 5.0 to 10.0
Numeric Pain Rating Scale (NPRS)
Worst NPRS score after standard stimulation
8.18 units on a scale
Interval 5.0 to 10.0
8.36 units on a scale
Interval 6.0 to 10.0
Numeric Pain Rating Scale (NPRS)
Average NPRS after 1000 Hz. stimulation
3.73 units on a scale
Interval 1.0 to 8.0
3.82 units on a scale
Interval 1.0 to 6.0
Numeric Pain Rating Scale (NPRS)
Average NPRS after standard stimulation
5.64 units on a scale
Interval 4.0 to 8.0
6.09 units on a scale
Interval 4.0 to 8.0
Numeric Pain Rating Scale (NPRS)
Worst NPRS score after 1000 Hz. stimulation
6.64 units on a scale
Interval 3.0 to 9.0
6.64 units on a scale
Interval 3.0 to 10.0
Numeric Pain Rating Scale (NPRS)
Worst NPRS after Wash off
8.72 units on a scale
Interval 6.0 to 10.0
8.81 units on a scale
Interval 7.0 to 10.0

SECONDARY outcome

Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)

Population: All study subjects were implanted with Boston Scientific's Precision Plus spinal cord stimulation system for treatment of chronic axial pain.

ODI is a outcome metrics that is design to assess the severity of disability based on 10 activity categories. ODI is based on 0 to 100% scale, where larger percentage implies worse disability. (There are 5 categories: 0-20%: Minimal disability, 21-40%: Moderate disability, 41-60%: Severe disability, 61-80%: Crippled. 81-100%: Either bed bound or exaggerating symptoms). ODI were measured at baseline (visit1), and at each follow ups visits at visit 2, 3 and 4. Visit 2 and 4 captured post treatment (either 1000 Hz or standard stimulation depending on the randomization) results, and visit 3 captured NPRS after the wash off from the spinal cord stimulation.

Outcome measures

Outcome measures
Measure
Treatment Group A
n=11 Participants
Subjects randomized to the treatment group A will begin the 7 week study with high frequency (1000Hz) sub-perception stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Treatment Group B
n=11 Participants
Subjects randomized to the treatment group B will begin the 7 week study with low frequency (40 to 50Hz) paresthesia capture stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency (1000Hz) sub-perception stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Oswestry Disability Index Questionnaire (ODI).
ODI after standard stimulation
49.63 units on a scale
Interval 28.0 to 70.0
49.05 units on a scale
Interval 30.0 to 58.0
Oswestry Disability Index Questionnaire (ODI).
Baseline ODI score
47.49 units on a scale
Interval 24.0 to 68.0
51.25 units on a scale
Interval 36.0 to 60.0
Oswestry Disability Index Questionnaire (ODI).
ODI after 1000 Hz. stimluation
39.23 units on a scale
Interval 24.0 to 66.0
33.77 units on a scale
Interval 16.0 to 54.0
Oswestry Disability Index Questionnaire (ODI).
ODI after wash off
52.87 units on a scale
Interval 20.0 to 76.0
56.77 units on a scale
Interval 32.0 to 78.0

SECONDARY outcome

Timeframe: Baseline (visit 1), and at each follow up visits (visits 2, 3, and 4)

Population: All study subjects were implanted with Boston Scientific's Precision Plus spinal cord stimulation system for treatment of chronic axial pain.

PGIC is a 7-point scale that requires study subjects to rate the severity of their illness or medical condition after a specific treatment. 1: No change, 2: Almost the same, 3: A little better, 4: Somewhat better, 5: Moderately better, 6: Better, 7: A great deal better. Study subjects were asked to report their impression of changes at baseline visit, visit 2 through 4.

Outcome measures

Outcome measures
Measure
Treatment Group A
n=11 Participants
Subjects randomized to the treatment group A will begin the 7 week study with high frequency (1000Hz) sub-perception stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Treatment Group B
n=11 Participants
Subjects randomized to the treatment group B will begin the 7 week study with low frequency (40 to 50Hz) paresthesia capture stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency (1000Hz) sub-perception stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Patient's Global Impression of Change (PGIC)
PGIC After 1000 Hz. stimulation
4.27 units on a scale
Interval 3.0 to 6.0
5.91 units on a scale
Interval 4.0 to 7.0
Patient's Global Impression of Change (PGIC)
PGIC after standard stimulation
2.54 units on a scale
Interval 1.0 to 7.0
2.45 units on a scale
Interval 1.0 to 6.0
Patient's Global Impression of Change (PGIC)
PGIC after Wash off
1.45 units on a scale
Interval 1.0 to 3.0
1.27 units on a scale
Interval 1.0 to 2.0

OTHER_PRE_SPECIFIED outcome

Timeframe: End of treatment visit on visit 4

Population: All study subjects were implanted with Boston Scientific's Precision Plus spinal cord stimulation system for treatment of chronic axial pain.

At the conclusion of the study, subjects were asked to report which spinal cord stimulation modes they preferred. Subjects were presented with two boxes (1000 Hz. stimulation and Standard stimulation) and asked to check one.

Outcome measures

Outcome measures
Measure
Treatment Group A
n=11 Participants
Subjects randomized to the treatment group A will begin the 7 week study with high frequency (1000Hz) sub-perception stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Treatment Group B
n=11 Participants
Subjects randomized to the treatment group B will begin the 7 week study with low frequency (40 to 50Hz) paresthesia capture stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency (1000Hz) sub-perception stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
Preferability
Subjects who prefer 1000 Hz. stimulation
8 participants
10 participants
Preferability
Subjects who prefer standard stimulation
3 participants
1 participants

Adverse Events

Treatment Group A

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Treatment Group B

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. James North MD

Center for Clinical Research / Carolinas Pain Institute

Phone: 3367656181

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place